FDA Brief

Warning letters Devices

FDA warning letter to

Lepu Medical Technology -Beijing- Co., Ltd.

High riskIssued Jul 29, 2021Posted Aug 10, 2021Center for Devices and Radiological Health

FDA warns Lepu Medical Technology Beijing that its unapproved COVID-19 test kits are adulterated and misbranded.

What happened

FDA reviewed Lepu Medical Technology (Beijing) Co., Ltd.'s offers for sale in the United States of Neutralization Antibody Test kits, a SARS-CoV-2 Antigen Rapid Test Kit, and a Saliva Antigen Rapid Test. FDA found the COVID-19 Test Kits were offered without marketing approval, clearance, or authorization and without the required 510(k) notification. The letter does not state an inspection; FDA based its findings on the product offerings.

What FDA found

  1. The firm offered COVID-19 test kits for sale in the United States without FDA marketing approval, clearance, or authorization.

    Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)
  2. The firm did not have an approved premarket approval (PMA) application or an approved investigational device exemption (IDE).

    Sections 515(a) and 520(g) of the Act, 21 U.S.C. §§ 360e(a), 360j(g)
  3. The firm did not notify FDA of its intent to introduce the devices into commercial distribution as required by 510(k).

    Section 502(o) of the Act, 21 U.S.C. § 352(o); Section 510(k), 21 U.S.C. § 360(k)
  4. The firm introduced or delivered for introduction the products into interstate commerce, which is prohibited.

    Section 301(a) of the Act, 21 U.S.C. § 331(a)
  5. The firm did acts with respect to the devices while held for sale after shipment in interstate commerce that resulted in misbranding.

    Section 301(k) of the Act, 21 U.S.C. § 331(k)

What FDA wants

FDA tells the firm to take immediate action to stop selling the unapproved, uncleared, and unauthorized COVID-19 test kits. Within 48 hours, the firm must email FDA with the specific steps taken, how it will prevent recurrence, and supporting documents; if it cannot act completely within 48 hours, it must state why and give a timeframe.

Who should pay attention

  • US buyers and distributors of COVID-19 test kits
  • labs and healthcare providers considering imported antigen or antibody tests
  • brands sourcing diagnostic tests from Chinese manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  3. Ostar Beauty Sci-Tech Co Ltd.

    FDA warned Ostar Beauty Sci-Tech, a Chinese maker of microneedling pens, LED masks and fat-freezing pads, for selling unapproved medical devices in the US.

    High risk
  4. RoyalVibe Health Ltd.

    RoyalVibe Health marketed unapproved medical devices for cancer and other diseases and refused an FDA inspection.

    High risk